Skip to main content

Table 4 Periprosthetic joint infection (PJI) and all surgical site infections (SSI) in various subgroups

From: Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties

  Total (n) PJI (n) p-value all SSI (n) p-value
Female 377 3   14  
Male 117 4 0.06a 5 0.78b
Procedure
 TKA1 254 7   11  
 THA2 240 0 0.015a 8 0.33b
BMI3, valid no 474
  < 30 368 4   12  
  > 30 106 3 0.19a 7 0.16 b
ASA4, valid no 451
  < 2 277 3   10  
  > 3 174 4 0.44a 8 0.60 b
Treatment
 Methotrexate 274 4 1.0a 12 0.49b
 TNF-alpha inhibitor 157 1 0.44a 5 0.60b
 Prednisolone 214 5 0.25a 10 0.40b
 Methotrexate and prednisolone 124 2 1.00a 4 0.79a
 Methotrexate and TNF-inhibitor 90 1 1.00a 3 1.00a
 Methotrexate, TNF- inhibitor and prednisolone 39 0 1.00a 0 0.39 a
Diagnosis
 Rheumatoid arthritis 341 6 0.45a 16 0.21a
 Psoriatic arthritis 35 1 0.40a 2 0.64a
 Spondyloarthritis incl. Ankylosing spondylitis 29 0 1.0a 0 1.0a
 Juvenile idiopathic arthritis 59 0 1.0a 1 0.76a
 Other diagnosis 30 0 1.0a 0 1.0a
  1. 1Total knee-arthroplasty, 2Total hip-arthroplasty, 3Body mass index, 4American Society of Anesthesiologists (ASA) Physical Status
  2. aFisher’s exact test
  3. bChi-square test